title: Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists.
abstract: Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has become mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences. In the present manuscript, we reviewed the few cases available in medical literature, regarding patients with G6PD deficiency treated with percutaneous coronary artery intervention (PCI) and DAPT, with the aim to discuss and clarify the optimal treatment in these patients.
authors.affiliation: Section of Internal and Cardiopulmonary Medicine, Department of Medical Science, University of Ferrara, Ferrara, Italy; Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Zuin
authors.affiliation: Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Rigatelli
authors.affiliation: Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Carraro
authors.affiliation: Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Galasso
authors.affiliation: Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Dell'Avvocata
authors.affiliation: Department of Oncoematology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Rossella
authors.initials: R
authors.lastname: Paolini
authors.affiliation: Section of Internal and Cardiopulmonary Medicine, Department of Medical Science, University of Ferrara, Ferrara, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Zuliani
authors.affiliation: Department of Cardiology, Rovigo General Hospital, Rovigo, Italy. Electronic address: roncon.loris@azisanrovigo.it.
authors.forename: Loris
authors.initials: L
authors.lastname: Roncon
mesh_terms: D000072096:Cardiologists; D003324:Coronary Artery Disease / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015642:Radiology, Interventional; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: Acute coronary syndrome; Antiplatelet therapy; G6PHD deficiency; Percutaneous coronary artery intervention